{"id":"trimetazidine-hydrochloride","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by inhibiting long-chain 3-ketoacyl CoA thiolase (3-KAT), which is involved in the breakdown of fatty acids in the mitochondria. This leads to a reduction in the production of reactive oxygen species and an increase in the production of ATP, resulting in improved cardiac function.","oneSentence":"Trimetazidine hydrochloride is a metabolic modulator that improves cardiac efficiency by optimizing energy production in heart cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:09.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Angina pectoris"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT04980716","phase":"PHASE3","title":"Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-06-01","conditions":"Non-small Cell Lung Cancer, Cardiovascular Complication","enrollment":524},{"nctId":"NCT04788745","phase":"PHASE2","title":"Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2021-06-29","conditions":"Amyotrophic Lateral Sclerosis, Motor Neuron Disease","enrollment":21},{"nctId":"NCT05556005","phase":"PHASE2","title":"Efficacy of Trimetazidine in Diabetic Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-09-18","conditions":"Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies","enrollment":60},{"nctId":"NCT04661709","phase":"PHASE4","title":"Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2021-03-01","conditions":"Coronary Heart Disease, Unstable Angina, Chinese Herbal Medicine","enrollment":502},{"nctId":"NCT04702906","phase":"NA","title":"Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2021-02","conditions":"Aluminum Phosphide Poisoning","enrollment":40},{"nctId":"NCT03274427","phase":"PHASE3","title":"Treatment of Intermediate-stage Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2017-07-18","conditions":"HCC","enrollment":300},{"nctId":"NCT03278444","phase":"PHASE3","title":"Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2017-07-18","conditions":"HCC","enrollment":300},{"nctId":"NCT03072082","phase":"PHASE4","title":"Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization","status":"UNKNOWN","sponsor":"Jun Li","startDate":"2017-06","conditions":"Coronary Artery Disease(CAD)","enrollment":440},{"nctId":"NCT03072121","phase":"PHASE4","title":"Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization","status":"UNKNOWN","sponsor":"Jun Li","startDate":"2017-06","conditions":"Coronary Artery Disease(CAD)","enrollment":440}],"_emaApprovals":[],"_faersSignals":[{"count":54,"reaction":"FALL"},{"count":29,"reaction":"DRUG INTERACTION"},{"count":25,"reaction":"CONFUSIONAL STATE"},{"count":25,"reaction":"OEDEMA PERIPHERAL"},{"count":25,"reaction":"RENAL FAILURE"},{"count":24,"reaction":"HYPONATRAEMIA"},{"count":24,"reaction":"MALAISE"},{"count":22,"reaction":"DIZZINESS"},{"count":22,"reaction":"DYSPNOEA"},{"count":21,"reaction":"SOMNOLENCE"}],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TH"],"phase":"phase_3","status":"active","brandName":"Trimetazidine hydrochloride","genericName":"Trimetazidine hydrochloride","companyName":"The First Affiliated Hospital of Zhengzhou University","companyId":"the-first-affiliated-hospital-of-zhengzhou-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trimetazidine hydrochloride is a metabolic modulator that improves cardiac efficiency by optimizing energy production in heart cells. Used for Angina pectoris, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}